A Pilot Randomised Controlled Dose‐Ranging Trial of Ant Venom Immunotherapy With and Without Delta‐Inulin Adjuvant
Clinical & Experimental Allergy · 2026
DOI: 10.1111/cea.70261 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical & Experimental Allergy, 2026. Verfasst von Thanh-Thao Adriana Le und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Allergy, Incorporating the Jack Jumper Allergy Program, Royal Hobart Hospital, Hobart, Tasmania, Australia. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, Ant Venoms, Desensitization, Immunologic, Insect Bites and Stings. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Services Charitable Gifts Board (Royal Adelaide Hospital), Allergy and Immunology Foundation of Australasia (Australasian Society of Clinical Immunology and Allergy), Australian Respiratory and Sleep Medicine Institute.
Abstract (Originalsprache)
Introduction
Jack Jumper ant (JJA) venom immunotherapy (VIT) is highly efficacious but the lowest effective dose is unknown. Delta‐inulin adjuvant (Advax) is known to enhance honeybee VIT immunogenicity.
Objective
This phase 1/2 single‐blind, randomised controlled trial aimed to compare the efficacy and safety of JJA VIT with different doses of venom ± Advax.
Methods
Adults aged 18–65 with a history of immediate systemic reaction (SR) to JJA stings were randomised to receive JJA VIT at a maintenance dose of 25 mcg or 50 mcg ± Advax; participants were blinded to treatment allocation. Primary outcomes were the response to sting challenges after 12 months and venom‐specific IgE and IgG4 responses to treatment.
Results
Forty‐nine of 50 screened subjects met inclusion criteria and were randomised; 44 started treatment (25 mcg n = 12; 25 mcg + Advax n = 13; 50mcg n = 12, 50 mcg + Advax n = 12). Subsequently, two withdrew due to SRs to treatment, and two withdrew due to unrelated factors. The higher JJA venom maintenance dose was associated with reduced likelihood of SRs (OR 0.53 (95% CI, 0.28–0.98)), while Advax did not have an effect (OR 1.17 (95% CI, 0.59–2.32)). Forty proceeded to sting challenge, with six developing SRs. There was no difference between groups for sting challenge outcome ( p = 0.98), and the ORs for 25 mcg vs. 50 mcg venom dose (0.89, 95% CI, 0.38–2.09) and Advax vs. no Advax (0.99, 95% CI 0.42–2.33) indicated no effect. There were no differences between groups for venom sIgE ( p = 0.78), sIgG4 ( p = 0.25), sIgE/IgG4 ratio ( p = 0.42), intradermal ( p = 0.77), and basophil activation test (BAT) ( p = 0.69) responses to treatment. Subjects with high baseline BAT sensitivity, which reduced markedly in response to treatment, were less likely to have a positive sting challenge ( p = 0.006).
Conclusion
Challenge outcomes were similar for all groups, with no significant difference found between 25 and 50 mcg maintenance dose or between treatment with and without Advax. Further research of low dose JJA VIT is warranted to confirm its efficacy and tolerability. Trial Registration NCT03066986
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Allergy, Incorporating the Jack Jumper Allergy Program, Royal Hobart Hospital, Hobart, Tasmania, Australia.
- College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.
- Immunology Directorate, SA Pathology, Adelaide, Australia.
- Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
- Adelaide Medical School, University of Adelaide, Adelaide, Australia.
- Rheumatology Research Group, Basil Hetzel Institute, Woodville South, South Australia, Australia.
ORCID-Profile: Thanh-Thao Adriana Le, Michael D Wiese, Nikolai Petrovsky
Förderung
- Health Services Charitable Gifts Board (Royal Adelaide Hospital)
- Allergy and Immunology Foundation of Australasia (Australasian Society of Clinical Immunology and Allergy)
- Australian Respiratory and Sleep Medicine Institute
- Royal Hobart Hospital Research Foundation
- Royal Adelaide Hospital
- Australasian Society of Clinical Immunology and Allergy
Zitieren
APA
Le, T. A., Wanandy, T., Perkins, G. B., Lester, S., Lau, W. Y., Turner, M., Woodman, R. J., Mulcahy, E. M., Joseph, S. V., Mhatre, S., Brown, S. G. A., Wiese, M. D., Petrovsky, N., Heddle, R. J., & Hissaria, P. (2026). A Pilot Randomised Controlled Dose‐Ranging Trial of Ant Venom Immunotherapy With and Without Delta‐Inulin Adjuvant. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70261
Vancouver
Le TA, Wanandy T, Perkins GB, Lester S, Lau WY, Turner M, et al. A Pilot Randomised Controlled Dose‐Ranging Trial of Ant Venom Immunotherapy With and Without Delta‐Inulin Adjuvant. Clinical & Experimental Allergy. 2026. doi:10.1111/cea.70261
BibTeX
@article{Le2026,
author = {Le, Thanh-Thao Adriana and Wanandy, Troy and Perkins, Griffith B and Lester, Susan and Lau, Wun Yee and Turner, Malcolm and Woodman, Richard J and Mulcahy, Emily M and Joseph, Sherin Vareeckal and Mhatre, Shweta and Brown, Simon G A and Wiese, Michael D and Petrovsky, Nikolai and Heddle, Robert J and Hissaria, Pravin},
title = {A Pilot Randomised Controlled Dose‐Ranging Trial of Ant Venom Immunotherapy With and Without Delta‐Inulin Adjuvant},
journal = {Clinical & Experimental Allergy},
year = {2026},
doi = {10.1111/cea.70261}
}
EUVIMED